IRCT20190412043247N1已完成3 期
Assessment the effects of Empagliflozin on laboratory markers in type 2 diabetic patients with coronary artery disease
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 40 years 至 75 years（—）
- 性别
- All
入选标准
- •Age between 40-75 year-old
- •HbA1c between 6.5 to 9
- •Diabetes mellitus type 2
- •Under fix continues treatment for at least 3 month
- •BMI less than 40
- •Fixed Diet and physical activity
排除标准
- •Heart Failure (NYHA class 3-4)
- •History of allergic reaction to SGLT2 inhibitors Drugs
- •History of SGLT2 inhibitor Drugs usage
- •Gastrointestinal malabsorbtion disease
- •History of CABG, ACS, TIA,CVA or PCI during past 3 month
- •History of mallingnacy
- •History of heart or lung transplant
- •Major psychiatric disorders
- •History of DKA
- •Elevated liver enzymes >3 times upper normal limit
- •Presence of urinary-genital infection
- •History of infection less than 1 month prior to the study
- •History of Anti-inflammatory drugs
研究者
相似试验
尚未招募
3 期
Evaluation of the effect of Empagliflozin on the severity of heart failure symptoms and echocardiography parameters in patients with congenital heart diseases with left-to-right shuntIRCT20120520009801N11Mashhad University of Medical Sciences44
已完成
3 期
Effect of Empagliflozin in prevention of kidney stone parametersIRCT20211203053261N2Hamedan University of Medical Sciences138
尚未招募
3 期
Assessment of effectiveness of Empagliflozin in the management of Anemia in diabetes patientsCTRI/2024/02/063292SRM Insitute of Science and Technology
已完成
1 期
Empagliflozin in non alcoholic fatty liverDiabetic patient with non alcoholic fatty liver.Other specified inflammatory liver diseasesK75.8IRCT20150706023084N18Islamic Azad University30
招募中
3 期
Effect of Empagliflozin in PrediabetesCondition 1: Impaired fasting glucose. Condition 2: Impaired glucose tolerance.Impaired fasting glucoseImpaired glucose tolerance (oral)R73.01R73.02IRCT20220902055858N1Shahre-kord University of Medical Sciences90